Dismay For Argenx As J&J Pulls Out Of Lucrative Blood Cancer Pact
Ends Partnership For Cusatuzumab
The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.
